Islet Cell Antibodies at Diagnosis, But Not Leanness, Relate to a Better Cardiovascular Risk Factor Profile 5 Years After Diagnosis of NIDDM


    loading  Checking for direct PDF access through Ovid

Abstract

OBJECTIVETo evaluate the relationship between islet cell antibodies (ICAs) and the cardiovascular risk profile 5 years after clinical diagnosis of NIDDM.RESEARCH DESIGN AND METHODSFive years after clinical diagnosis, we evaluated blood pressure (BP) and lipids in 17 NIDDM patients with ICA at diagnosis (age 60 plus/minus 4 years) and 133 NIDDM patients without ICA at diagnosis (age 61 plus/minus 1 year). Urinary albumin excretion was evaluated in a subset of 12 NIDDM patients with ICA at diagnosis (age 60 plus/minus 4 years) and 82 NIDDM patients without ICA at diagnosis (age 61 plus/minus 1 year).RESULTSNIDDM patients without ICA showed higher BP (140/86 plus/minus 2/1 mmHg vs. 128/79 plus/minus 3/2 mmHg; P less than 0.05), total cholesterol (6.10 plus/minus 0.11 vs. 5.09 plus/minus 0.29 mmol/l; P less than 0.01), LDL-to-HDL ratio (3.85 plus/minus 0.14 vs. 2.49 plus/minus 0.18; P less than 0.001), and triglycerides (2.58 plus/minus 0.24 vs. 0.90 plus/minus 0.06 mmol/l; P less than 0.001), lower HDL cholesterol (1.08 plus/minus 0.03 vs. 1.40 plus/minus 0.08 mmol/l; P less than 0.001), and higher urinary albumin excretion (0.16 plus/minus 0.06 vs. 0.01 plus/minus 0.01 g/24 h; P less than 0.05) than NIDDM patients with ICA. Among NIDDM patients without ICA, no differences concerning BP or lipids were found between obese and nonobese patients.CONCLUSIONSICA at diagnosis of NIDDM is a marker of more favorable cardiovascular risk profile 5 years after clinical diagnosis.

    loading  Loading Related Articles